Vicentini Quentin, Hekman Dennis, Bhatt Deepak, Stulz Rouven, Dezfouli Mahya, Gennemark Peter, Guzzi Nicola, Toki Naoko, Lazovic Bojana, Tängemo Carolina, Andersson Shalini, El Andaloussi Samir, Dahlén Anders
Cell, Genes and RNA Therapy, Discovery Sciences, Biopharmaceuticals R&D-AstraZeneca Gothenburg, 43183 Mölndal, Sweden.
Division of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152 Stockholm, Sweden.
Bioconjug Chem. 2025 Jun 18;36(6):1299-1310. doi: 10.1021/acs.bioconjchem.5c00156. Epub 2025 May 29.
Oligonucleotide therapeutics (ONT) traditionally involve a single targeting moiety per oligonucleotide when conjugated for organ delivery. Multimerization represents a novel approach by connecting multiple ONTs to a single scaffold, thereby influencing the drug's activity and biophysical properties . Recently, others have demonstrated the efficacy of this strategy, showing enhanced tissue retention and extended silencing with the capability to target multiple genes simultaneously. The investigation of diverse multimeric designs is thus an exciting opportunity to explore the delivery of the ONT. In this study, we engineered a versatile peptide branching unit able to link up to four small interfering RNAs together. We conjugated a GalNAc targeting moiety to these scaffolds for liver hepatocyte delivery and assessed their silencing activity. Our approach was further expanded to explore different peptide architectures (linear versus cyclized) and additional functionalities, including endosomal escape domains and dual target silencing. We then evaluated the constructs via subcutaneous and intravenous (i.v.) administration in mice. Notably, the intravenous administration of multimeric siRNA GalNAc demonstrated potent silencing in the liver and significantly affected liver-to-kidney biodistribution. Our findings suggest that peptides as branching units offer a promising pathway for ONT multimerization, advancing the challenges of drug delivery.
传统上,寡核苷酸疗法(ONT)在进行器官递送偶联时,每个寡核苷酸仅涉及一个靶向部分。多聚化是一种新方法,通过将多个ONT连接到单个支架上,从而影响药物的活性和生物物理性质。最近,其他人已经证明了这种策略的有效性,显示出增强的组织滞留和延长的沉默效果,同时具有靶向多个基因的能力。因此,研究各种多聚体设计是探索ONT递送的一个令人兴奋的机会。在本研究中,我们设计了一种通用的肽分支单元,能够将多达四个小干扰RNA连接在一起。我们将一个GalNAc靶向部分偶联到这些支架上,用于肝脏肝细胞递送,并评估了它们的沉默活性。我们的方法进一步扩展,以探索不同的肽结构(线性与环化)和其他功能,包括内体逃逸结构域和双靶点沉默。然后,我们通过皮下和静脉内(i.v.)给药在小鼠中评估了这些构建体。值得注意的是,多聚体siRNA GalNAc的静脉内给药在肝脏中显示出有效的沉默作用,并显著影响了肝脏与肾脏的生物分布。我们的研究结果表明,肽作为分支单元为ONT多聚化提供了一条有前景的途径,推动了药物递送方面的挑战。